S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.36%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Actualizaciones en tiempo real para Amgen Inc [AMG.DE]

Bolsa: XETRA Sector: Biotechnology Industria: Drug Manufacturers—General
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-05-01)

Expected move: +/- 0.00%

Última actualización26 abr 2024 @ 11:35

0.78% 252.25

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:35):

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...

Stats
Volumen de hoy 136.00
Volumen promedio 594.00
Capitalización de mercado 135.19B
EPS €0 ( 2024-04-24 )
Próxima fecha de ganancias ( €0 ) 2024-05-01
Last Dividend €2.13 ( 2023-08-17 )
Next Dividend €0 ( N/A )
P/E 21.63
ATR14 €0.724 (0.29%)

Amgen Inc Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amgen Inc Finanzas

Annual 2023
Ingresos: €28.19B
Beneficio Bruto: €19.74B (70.02 %)
EPS: €12.56
FY 2023
Ingresos: €28.19B
Beneficio Bruto: €19.74B (70.02 %)
EPS: €12.56
FY 2022
Ingresos: €26.32B
Beneficio Bruto: €19.92B (75.66 %)
EPS: €12.18
FY 2021
Ingresos: €25.98B
Beneficio Bruto: €19.53B (75.16 %)
EPS: €9.74

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€1.940
(N/A)
€1.940
(N/A)
€2.13
(N/A)
€2.13
(N/A)
€2.13
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Amgen Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.55 - Stable (8.94%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.280 2011-08-16
Last Dividend €2.13 2023-08-17
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 49 --
Total Paid Out €56.75 --
Avg. Dividend % Per Year 0.00% --
Score 4.22 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.55
Div. Directional Score 7.43 --
Next Divdend (Est)
(2024-07-01)
€2.17 Estimate 22.19 %
Dividend Stability
0.59 Average
Dividend Score
4.22
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
JNJ.DE Ex Dividend Knight 2023-08-25 Quarterly 0 0.00%
TA1.DE Ex Dividend Knight 2023-06-12 Annually 0 0.00%
DEF.DE Ex Dividend Knight 2023-07-24 Annually 0 0.00%
MMM.DE Ex Dividend Junior 2023-08-18 Quarterly 0 0.00%
4I1.DE Ex Dividend Knight 2023-09-26 Quarterly 0 0.00%
VVD.DE Ex Dividend Knight 2023-05-09 Annually 0 0.00%
EVK.DE Ex Dividend Junior 2023-06-01 Annually 0 0.00%
OMV.DE Ex Dividend Knight 2023-06-06 Annually 0 0.00%
AMG.DE Ex Dividend Knight 2023-08-17 Quarterly 0 0.00%
HAW.DE Ex Dividend Junior 2023-06-13 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2381.5005.237.85[0 - 0.5]
returnOnAssetsTTM0.06911.2007.709.23[0 - 0.3]
returnOnEquityTTM1.0331.50010.0010.00[0.1 - 1]
payoutRatioTTM0.678-1.0003.22-3.22[0 - 1]
currentRatioTTM1.6490.8006.755.40[1 - 3]
quickRatioTTM1.0270.8008.676.93[0.8 - 2.5]
cashRatioTTM0.5951.5007.8110.00[0.2 - 2]
debtRatioTTM0.665-1.50010.00-10.00[0 - 0.6]
interestCoverageTTM3.151.0009.949.94[3 - 30]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
freeCashFlowPerShareTTM13.762.003.126.24[0 - 20]
debtEquityRatioTTM10.37-1.50010.00-10.00[0 - 2.5]
grossProfitMarginTTM0.7001.0001.6631.663[0.2 - 0.8]
operatingProfitMarginTTM0.3211.0005.575.57[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1311.000-0.383-0.383[0.2 - 2]
assetTurnoverTTM0.2900.800-1.399-1.119[0.5 - 2]
Total Score10.30

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM21.501.0007.930[1 - 100]
returnOnEquityTTM1.0332.503.3410.00[0.1 - 1.5]
freeCashFlowPerShareTTM13.762.005.416.24[0 - 30]
dividendYielPercentageTTM3.201.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
payoutRatioTTM0.6781.5003.22-3.22[0 - 1]
pegRatioTTM-5.581.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3001.0004.990[0.1 - 0.5]
Total Score4.55

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico